Stockscreener 앱 받기
1,049.99
2.04%
22.48
Lilly Eli Co 주식(LLY)의 최신 뉴스
Eli Lilly (LLY): B of A Securities Lowers Price Target Despite Buy Rating | LLY Stock News - GuruFocus
Lilly Building $6B Huntsville Pharma Plant - Connect CRE
V. M. Manning & CO. Inc. Invests $875,000 in Eli Lilly and Company $LLY - MarketBeat
Bank of America Has Lowered Expectations for Eli Lilly and Company (NYSE:LLY) Stock Price - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Julie Johnson - MarketBeat
Eli Lilly price target raised to $1,145 from $951 at Goldman Sachs - TipRanks
Eli Lilly and Company $LLY Shares Purchased by NWF Advisory Services Inc. - MarketBeat
Silicon Valley Capital Partners Boosts Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by SevenBridge Financial Group LLC - MarketBeat
Orion Porfolio Solutions LLC Has $39.62 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly & Co: Strategic Initiatives and Promising Market Opportunities Drive Buy Rating - TipRanks
Thrivent Financial for Lutherans Acquires 52,783 Shares of Eli Lilly and Company $LLY - MarketBeat
MASTERINVEST Kapitalanlage GmbH Acquires New Holdings in Eli Lilly and Company $LLY - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Trims Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Just Delivered Fantastic News to Investors - Finviz
Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) (NYSE:LLY) - Seeking Alpha
Cim Investment Management Inc. Has $3.12 Million Stake in Eli Lilly and Company $LLY - MarketBeat
American Trust Buys 3,644 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) Expands Mounjaro Use to Younger Patients in Euro - GuruFocus
Eli Lilly’s Retatrutide Study: A New Hope for CKD Treatment? - TipRanks
Eli Lilly’s New Study on Obesity Drug LY4167586: What Investors Need to Know - TipRanks
Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment - TipRanks
Eli Lilly Completes Phase 1 Study of Eloralintide for Obesity in China - TipRanks
Eli Lilly Weight Loss Drug Shows Impressive Results in Phase 3 Trial - InsideHook
2 Predictions for Novo Nordisk in 2026 - The Motley Fool
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025) - ts2.tech
Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus - MSN
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025) - ts2.tech
Liontrust Investment Partners LLP Grows Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Rexford Capital Inc. Purchases Shares of 1,488 Eli Lilly and Company $LLY - MarketBeat
Public Sector Pension Investment Board Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Castleark Management LLC Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Brick & Kyle Associates Purchases 1,700 Shares of Eli Lilly and Company $LLY - MarketBeat
Advisory Services Network LLC Buys 1,351 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - MSN
Eli Lilly’s Stock Sets a New Industry Standard - AD HOC NEWS
Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far? - simplywall.st
Eli Lilly: The Right Long-Term Strategy - Seeking Alpha
Eli Lilly and Company $LLY is Banque Transatlantique SA's 10th Largest Position - MarketBeat
Blue Capital Inc. Takes Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by AQR Capital Management LLC - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Ameriprise Financial Inc. - MarketBeat
Adage Capital Partners GP L.L.C. Raises Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Further Cements Itself As The King Of Weight Loss (NYSE:LLY) - Seeking Alpha
Why the Market Dipped But Eli Lilly (LLY) Gained Today - sharewise.com
Eli Lilly and Company (NYSE:LLY) Shares Up 1.8%Here's Why - MarketBeat
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next - ts2.tech
Clinical trials reveal promising results for new Eli Lilly drug - NewsNation
What's Going On With Eli Lilly Stock Friday?Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly to Build $6-Billion Alabama Facility - AdvancedManufacturing.org
Moody’s affirms Eli Lilly’s Aa3 rating, outlook revised to positive By Investing.com - Investing.com Nigeria
Eli Lilly (LLY) Reports Promising Results from Phase 3 EMBER-3 S - GuruFocus
Eli Lilly announces updated results from Phase 3 EMBER-3 study of Inluriyo - TipRanks
Exclusive: FDA leaders pushed to cut Lilly weight-loss pill review time - Reuters
Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history - Fierce Pharma
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win - Yahoo Finance
Eli Lilly touts strong results of new experimental weight loss drug retatrutide - Straight Arrow News
Eli Lilly Stock Rises After Late-Stage Data Shows Longer Survival With Breast Cancer Drug - Stocktwits
U.S. Regulators Pushed to Fast-Track Approval of Eli Lilly’s (LLY) Weight-Loss Pill: Reports - TipRanks
Eli Lilly (LLY) Gains EU Support for Mounjaro Use in Younger Pat - GuruFocus
EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above - Reuters
Lilly to build $6B weight-loss drug factory in Alabama - Construction Dive
Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial - Reuters
Truist Securities reiterates Buy rating on Eli Lilly stock at $1,182 - Investing.com
Lilly to Invest $6B in New API Manufacturing Facility in Alabama - Contract Pharma
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025) - ts2.tech
US FDA likely to speed up evaluation of Eli Lilly's weight loss pill - medwatch.com
Eli Lilly (LLY) Boosts Dividend by 15.3% - GuruFocus
Eli Lilly & Co: Promising Future with Strong TRIUMPH-4 Trial Results and Strategic Pipeline Driving Growth - TipRanks
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025) - 24/7 Wall St.
0.23%
자본화:
|
볼륨(24시간):